Figure 6.
Influence of diacylglycerol-lipase (DAGL) inhibitor Orlistat on the peak effects of angiotensin II (Ang II) on coronary flow (A) and left ventricular developed pressure (LVDevP) (B) of isolated rat hearts. Ang II (10−7 M) was administered repetitively to the perfusate. The presented data were recorded during the second infusion period when Ang II was infused either in the presence of DAGL inhibitor Orlistat (10−5 M) or its vehicle and are expressed as relative values compared to pre-infusion control data. Mean ± SEM; n = 4 & 6; * p < 0.05 and ** p < 0.01 vs. control (pre-infusion value) paired t-test; # p < 0.05 and ns: non-significant vs. Ang II +vehicle; t-test.